Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients
- PMID: 8270973
- DOI: 10.1200/JCO.1994.12.1.159
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients
Abstract
Purpose: This study was performed to identify risk factors of ifosfamide-induced renal damage.
Patients and methods: Renal function was assessed in 120 patients at a minimum of 3 months after completion of chemotherapy including ifosfamide. The cumulative ifosfamide dose ranged from 2 to 95 g/m2 (median, 30 g/m2). Ten patients had undergone unilateral nephrectomy; combination cytostatic treatment included cisplatin in 51 and methotrexate in 57. Sixty-eight patients had received gentamicin treatment. The glomerular filtration rate was estimated using the Schwartz formula. Proximal tubular function was assessed by the percent reabsorptions of glucose and 16 amino acids, the fractional excretion of sodium, and the fractional reabsorption of phosphate. In addition, the serum bicarbonate level was measured.
Results: Proximal tubular dysfunction--with a predominance of renal amino acid (66.3%) and phosphate loss (38.3%)--was much more frequent than both glomerular impairment and acidosis. Seven patients were identified as having renal Fanconi's syndrome, and generalized tubulopathy was noted in another 15 patients. Ifosfamide-induced nephrotoxicity was dose-dependent, with a weak linear inverse correlation between cumulative ifosfamide dose and fractional phosphate reabsorption. Unilateral nephrectomy proved to be the single most important risk factor (odds ratio for the development of renal Fanconi's syndrome, 11.4), but cisplatin also significantly enhanced ifosfamide-mediated nephrotoxicity. Methotrexate, gentamicin, and patient age at primary diagnosis had no influence on renal function.
Conclusion: Ifosfamide chemotherapy should probably be restricted in patients after unilateral nephrectomy.
Similar articles
-
[Ifosfamide-induced nephrotoxicity].Monatsschr Kinderheilkd. 1993 Jul;141(7):594-601. Monatsschr Kinderheilkd. 1993. PMID: 8413339 Clinical Trial. German.
-
Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum.Med Pediatr Oncol. 1994;22(1):27-32. doi: 10.1002/mpo.2950220106. Med Pediatr Oncol. 1994. PMID: 8232077
-
Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.Pediatr Nephrol. 1994 Apr;8(2):151-6. doi: 10.1007/BF00865464. Pediatr Nephrol. 1994. PMID: 8018491
-
Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.Cochrane Database Syst Rev. 2019 Mar 11;3(3):CD008944. doi: 10.1002/14651858.CD008944.pub3. Cochrane Database Syst Rev. 2019. PMID: 30855726 Free PMC article.
-
Chronic ifosfamide nephrotoxicity in children.Med Pediatr Oncol. 2003 Sep;41(3):190-7. doi: 10.1002/mpo.10336. Med Pediatr Oncol. 2003. PMID: 12868118 Review.
Cited by
-
Ewing tumour: incidence, prognosis and treatment options.Paediatr Drugs. 2001;3(12):899-913. doi: 10.2165/00128072-200103120-00003. Paediatr Drugs. 2001. PMID: 11772151 Review.
-
Nephrotoxicity as a cause of acute kidney injury in children.Pediatr Nephrol. 2008 Dec;23(12):2159-73. doi: 10.1007/s00467-007-0721-x. Epub 2008 Jan 29. Pediatr Nephrol. 2008. PMID: 18228043 Free PMC article. Review.
-
Genitourinary long-term outcomes for childhood cancer survivors.Curr Urol Rep. 2009 Mar;10(2):134-7. doi: 10.1007/s11934-009-0024-9. Curr Urol Rep. 2009. PMID: 19239818 Review.
-
Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol.Nat Rev Urol. 2018 May;15(5):309-319. doi: 10.1038/nrurol.2018.14. Epub 2018 Feb 27. Nat Rev Urol. 2018. PMID: 29485128 Review.
-
Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma.Sarcoma. 1999;3(2):95-9. doi: 10.1080/13577149977712. Sarcoma. 1999. PMID: 18521270 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical